Dedicated to Conquering Heart Failure

A clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease

COVID-19 and CVD

Cardiol has been approved by the FDA for a Phase II/III clinical trial to test the efficacy of CardiolRx™ in improving outcomes for COVID-19 patients with cardiovascular disease (CVD).

Learn More

Acute Myocarditis

Cardiol is planning a Phase II international trial of acute myocarditis, the most common cause of sudden cardiac death in people under 35 years of age.

Learn More

Heart Failure

Committed to conquering a serious condition that affects more than 26 million people globally.

Learn More


All News


In an interview with Pharmacy Times®, Guillermo Torre-Amione, MD, PhD, FACC, the Chairman of Cardiol Therapeutics, discusses the potential use for cannabidiol (CBD) in hospitalized patients with COVID-19, as well as its therapeutic benefits in certain patients with cardiovascular disease.

In this discussion, Dr. Torre-Amione explains the potential benefits for anti-inflammatory therapies for these patients, as well as how CBD specifically can be applied. He also describes a use for CBD in treating cardiovascular disease related to viral damage, and what other anti-inflammatory therapies may soon be available.